Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypothyroidism | 13 | 2023 | 32 | 3.800 |
Why?
|
| Triiodothyronine | 12 | 2023 | 28 | 2.620 |
Why?
|
| Hormone Replacement Therapy | 7 | 2023 | 30 | 2.610 |
Why?
|
| Iodide Peroxidase | 12 | 2021 | 34 | 2.350 |
Why?
|
| Thyroxine | 10 | 2023 | 25 | 2.200 |
Why?
|
| Thyroid Hormones | 5 | 2016 | 13 | 1.610 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 307 | 1.030 |
Why?
|
| Homeostasis | 3 | 2015 | 84 | 1.020 |
Why?
|
| Transcriptome | 3 | 2016 | 84 | 0.990 |
Why?
|
| Energy Metabolism | 3 | 2014 | 53 | 0.930 |
Why?
|
| Thyroid Gland | 4 | 2021 | 26 | 0.920 |
Why?
|
| Thyroid Diseases | 2 | 2018 | 13 | 0.660 |
Why?
|
| Adipose Tissue | 2 | 2015 | 74 | 0.600 |
Why?
|
| Obesity | 3 | 2015 | 290 | 0.570 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 7 | 0.550 |
Why?
|
| Insulin Infusion Systems | 1 | 2016 | 3 | 0.540 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 38 | 0.530 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 55 | 0.520 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 51 | 0.520 |
Why?
|
| Pericardium | 1 | 2015 | 20 | 0.510 |
Why?
|
| Humans | 27 | 2023 | 29851 | 0.500 |
Why?
|
| Mitochondria | 1 | 2015 | 84 | 0.500 |
Why?
|
| Thermogenesis | 2 | 2014 | 3 | 0.490 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 140 | 0.480 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2014 | 1 | 0.470 |
Why?
|
| Hypothalamus | 1 | 2014 | 6 | 0.470 |
Why?
|
| Liver | 1 | 2015 | 175 | 0.470 |
Why?
|
| Adipose Tissue, Brown | 1 | 2013 | 4 | 0.460 |
Why?
|
| Animals | 14 | 2021 | 4639 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 334 | 0.460 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 125 | 0.450 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 149 | 0.430 |
Why?
|
| Signal Transduction | 2 | 2018 | 491 | 0.410 |
Why?
|
| Exercise | 1 | 2016 | 474 | 0.390 |
Why?
|
| Alzheimer Disease | 3 | 2022 | 2005 | 0.390 |
Why?
|
| Cognitive Dysfunction | 4 | 2022 | 969 | 0.380 |
Why?
|
| Amino Acid Substitution | 3 | 2018 | 26 | 0.320 |
Why?
|
| Threonine | 2 | 2018 | 7 | 0.280 |
Why?
|
| Fatty Liver | 2 | 2018 | 31 | 0.280 |
Why?
|
| Alanine | 2 | 2018 | 11 | 0.280 |
Why?
|
| Gene Frequency | 2 | 2018 | 75 | 0.280 |
Why?
|
| Mice | 8 | 2021 | 1628 | 0.270 |
Why?
|
| Astrocytes | 3 | 2018 | 122 | 0.270 |
Why?
|
| Basal Metabolism | 2 | 2016 | 4 | 0.250 |
Why?
|
| Hippocampus | 2 | 2018 | 285 | 0.250 |
Why?
|
| Case-Control Studies | 2 | 2018 | 643 | 0.240 |
Why?
|
| Male | 11 | 2022 | 15871 | 0.230 |
Why?
|
| Dementia | 2 | 2019 | 527 | 0.230 |
Why?
|
| United States | 3 | 2019 | 2346 | 0.210 |
Why?
|
| Mice, Knockout | 6 | 2021 | 309 | 0.200 |
Why?
|
| Tissue Extracts | 1 | 2021 | 14 | 0.200 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 86 | 0.180 |
Why?
|
| Gene Expression | 2 | 2018 | 232 | 0.180 |
Why?
|
| Quality of Life | 2 | 2021 | 677 | 0.180 |
Why?
|
| Thyrotropin | 2 | 2016 | 11 | 0.170 |
Why?
|
| Neuropathology | 1 | 2019 | 81 | 0.170 |
Why?
|
| Female | 8 | 2022 | 16430 | 0.170 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 4 | 0.170 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 7 | 0.160 |
Why?
|
| HEK293 Cells | 2 | 2018 | 69 | 0.160 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 77 | 0.160 |
Why?
|
| Amiodarone | 1 | 2018 | 29 | 0.160 |
Why?
|
| Microarray Analysis | 2 | 2015 | 8 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 446 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2018 | 131 | 0.160 |
Why?
|
| Hospitals | 1 | 2019 | 157 | 0.160 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2018 | 7 | 0.150 |
Why?
|
| Status Epilepticus | 1 | 2018 | 50 | 0.150 |
Why?
|
| Hypercholesterolemia | 1 | 2018 | 29 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2019 | 138 | 0.150 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2018 | 110 | 0.150 |
Why?
|
| Biomarkers | 2 | 2022 | 704 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2018 | 685 | 0.140 |
Why?
|
| Aged | 6 | 2021 | 9621 | 0.140 |
Why?
|
| Osteoarthritis | 1 | 2021 | 366 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2016 | 64 | 0.140 |
Why?
|
| Iodine | 1 | 2016 | 2 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 263 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2016 | 20 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 32 | 0.130 |
Why?
|
| Hepatocytes | 1 | 2015 | 10 | 0.130 |
Why?
|
| Protein Binding | 1 | 2016 | 125 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2016 | 91 | 0.130 |
Why?
|
| Adult | 4 | 2021 | 8748 | 0.130 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 71 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 80 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 33 | 0.130 |
Why?
|
| Ubiquitination | 1 | 2015 | 11 | 0.130 |
Why?
|
| Anxiety | 1 | 2016 | 157 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4930 | 0.130 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2015 | 14 | 0.130 |
Why?
|
| HeLa Cells | 1 | 2015 | 52 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 29 | 0.120 |
Why?
|
| Syndrome | 1 | 2015 | 88 | 0.120 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 14 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2014 | 16 | 0.120 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 273 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 106 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2014 | 39 | 0.120 |
Why?
|
| Uncoupling Protein 1 | 1 | 2013 | 1 | 0.120 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 7 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2015 | 403 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 201 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 21 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2014 | 84 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2014 | 165 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 285 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2015 | 197 | 0.110 |
Why?
|
| Brain | 2 | 2021 | 1727 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2013 | 166 | 0.110 |
Why?
|
| Depression | 1 | 2016 | 472 | 0.100 |
Why?
|
| Ion Channels | 1 | 2013 | 190 | 0.100 |
Why?
|
| Models, Biological | 1 | 2013 | 347 | 0.100 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 355 | 0.090 |
Why?
|
| Middle Aged | 3 | 2021 | 9963 | 0.090 |
Why?
|
| Thyroid Function Tests | 2 | 2018 | 8 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1187 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2021 | 1824 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2021 | 3561 | 0.050 |
Why?
|
| Desiccation | 1 | 2021 | 5 | 0.050 |
Why?
|
| Cognition | 2 | 2022 | 1314 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 80 | 0.050 |
Why?
|
| tau Proteins | 1 | 2022 | 213 | 0.050 |
Why?
|
| Placebos | 1 | 2021 | 82 | 0.050 |
Why?
|
| Paired Box Transcription Factors | 1 | 2021 | 2 | 0.050 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 2 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2021 | 3 | 0.050 |
Why?
|
| Gene Editing | 1 | 2021 | 6 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 10 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2021 | 82 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2021 | 21 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2021 | 55 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2022 | 302 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2021 | 133 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 109 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2021 | 522 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2021 | 124 | 0.040 |
Why?
|
| Cartilage | 1 | 2021 | 154 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 364 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 214 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 494 | 0.040 |
Why?
|
| Benchmarking | 1 | 2019 | 42 | 0.040 |
Why?
|
| Golgi Apparatus | 1 | 2018 | 4 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 39 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2018 | 22 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 27 | 0.040 |
Why?
|
| Muscarinic Agonists | 1 | 2018 | 1 | 0.040 |
Why?
|
| Pilocarpine | 1 | 2018 | 2 | 0.040 |
Why?
|
| Cell Death | 1 | 2018 | 62 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2018 | 80 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 50 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 256 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 744 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 1247 | 0.040 |
Why?
|
| Apoptosis | 1 | 2018 | 259 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 532 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 153 | 0.040 |
Why?
|
| Hindlimb Suspension | 1 | 2016 | 2 | 0.040 |
Why?
|
| Physical Conditioning, Animal | 1 | 2016 | 7 | 0.040 |
Why?
|
| Mental Status Schedule | 1 | 2016 | 114 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 96 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 347 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 57 | 0.030 |
Why?
|
| Calorimetry, Indirect | 1 | 2015 | 3 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2015 | 17 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2015 | 58 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 258 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 51 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 874 | 0.030 |
Why?
|
| Neurons | 1 | 2018 | 381 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2015 | 42 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 327 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 160 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 41 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2015 | 83 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 56 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 128 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 31 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 759 | 0.030 |
Why?
|
| Eating | 1 | 2014 | 46 | 0.030 |
Why?
|
| Bone Density | 1 | 2014 | 151 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 867 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2014 | 61 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 812 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 970 | 0.030 |
Why?
|
| Rats | 1 | 2015 | 877 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1462 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 1641 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 1859 | 0.020 |
Why?
|